After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Former Arkansas School for Mathematics, Sciences, and the Arts student Claire Green, now attending Mississippi State ...

David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

Shares of Scholar Rock Holdings (SRRK) jumped nearly 15% in intraday trading Wednesday after the biopharmaceutical firm reported positive results from a weight-loss drug trial. 1 ...

Scholar Rock, a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy and additional severe and debilitating ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly. Scholar Rock, a biopharma company ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and ...

Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.

Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.

That handily beat the S&P 500 index, which itself had a good trading session with a 1.7% advance. Bulking up Scholar Rock targets relatively uncommon disorders that might lack effective treatments.